ZRANB2-AS2

Across TCGA pan-cancer cohorts, ZRANB2-AS2 RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated ZRANB2-AS2 data layer.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZRANB2-AS2 RNA is associated with better overall survival. In most high-consensus cancer types, elevated ZRANB2-AS2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and KIRC show a favorable association.

LUAD, BLCA, and KIRC are the cancer types where ZRANB2-AS2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.746	0.584	.002	75	view →
BLCA	OS	Median	IV	0.322	0.774	<.001	60	view →
KIRC	DFS	Tertile	All	0.850	0.729	<.001	53	view →
BRCA	DFS	Median	III,IV	0.929	0.827	.002	38	view →
READ	DFS	Median	All	0.400	0.775	.004	23	view →
ACC	DFS	Quartile	III,IV	0.693	0.072	.006	20	view →
MESO	DFS	Tertile	All	0.315	0.669	.012	18	view →
UCS	OS	Tertile	II,III,IV	0.579	0.206	.018	16	view →
ESCA	OS	Quartile	IV	0.127	0.713	.038	12	view →
STAD	OS	Tertile	All	0.426	0.594	.021	12	view →
KIRP	DFS	Median	All	0.918	0.596	.005	10	view →
PRAD	DFS	Quartile	All	0.926	0.830	.016	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

ZRANB2-AS2–LUAD (OS)

Open the LUAD breakdown →